SmartKem has stopped being an electronics-materials operating company in any economic sense and is now a Nasdaq listing wrapper around a pending all-stock purchase of Ferrox, a British Virgin Islands minerals developer whose main asset is the Tivani iron-titanium-vanadium project in Limpopo, South Africa. The June quarter closed with no product sales after the United Kingdom operating subsidiary entered creditors' voluntary liquidation in mid June. Management states there is substantial doubt the parent can meet obligations over the next year, and that this doubt is not alleviated by current financing plans. The investment case is no longer about organic thin-film transistors reaching a display foundry. It is about whether a tiny common equity can survive dilution long enough for a minerals combination to close.
What actually moved under the hood is a cash-and-paper reshuffle, not a materials ramp. Mid-year cash sat at $3.7 million. That figure is larger than year-end cash only because equity and preferred raises brought in more than $13 million of financing inflows. Almost $6.5 million of that cash was immediately lent to Ferrox as convertible notes. Those notes are carried at a $6.2 million fair value that rests on unobservable assumptions. Operating expenses were cut hard after the subsidiary liquidation, but revenue also vanished. The parent now reports no plant, no leases, and no research-tax-credit receivable. The remaining economic assets are cash, a Level Three claim on Ferrox, and process know-how described as forty trade secrets after the patent portfolio was transferred in a settlement.
The second quarter printed a net loss of $3.3 million on zero revenue. That print follows a first-half loss of $22.6 million. The half-year figure is dominated by the liquidation accounting and a large non-cash charge for commitment shares on the equity line. A reverse split in late August restored the Nasdaq bid-price test after a string of sessions above the exchange minimum. Common last closed at $2.19. Market value is roughly $1.2 million. Mid-year book equity is $9.7 million. The open question is whether stockholder approval of the Ferrox combination, and a demonstration concentrate run at Tivani later this year, arrive before cash and listing patience run out.